Increase in HIV-1 transmitted drug resistance among untreated 16~25-y-old youths in the China-Myanmar border areas during 2009~2017

Background Transmitted drug resistance (TDR) can affect antiretroviral therapy (ART) efficacy. Surveillance drug resistance mutations in untreated youths newly reported with HIV-1 are highly representative of local TDR. We investigated HIV-1 TDR, TDR transmission based on molecular networks, and the effect of TDR mutations (TDRMs) on the CD4 count among youths in the China-Myanmar border area near the "Golden Triangle" to better understand TDR and guide ART.Methods From 2009 to 2017, 573 ART-naïve youths (16~25 y) newly reported with HIV-1 were enrolled. CD4 counts were obtained from whole blood. HIV pol gene sequences were amplified from RNA extracted from plasma. The Stanford REGA program and phylogenetic trees were used to determine genotypes. TDRMs were analyzed using the Stanford Calibrated Population Resistance tool. TDR transmission was evaluated from molecular networks of HIV-1 pol genes.Results The average prevalence of TDR was 6.3%, and the resistance to NNRTIs, NRTIs, and PIs was 3.49%, 2.62%, and 0.52%, respectively. TDR prevalence increased significantly during the period 2009~2017 (3.92%~9.48%, p<0.05). The mean CD4 count was significantly lower among individuals with TDRMs (373/mm3 vs. 496/mm3, p=0.013). The rate of network entry of youths harboring TDRMs (63.89%) was significantly higher than that of youths without TDRMs (44.9%).Conclusions The HIV-1 TDR increase and low CD4 count of patients with TDRMs in Dehong at the China-Myanmar border suggest the need for early ART and completion of resistance testing before initiating ART in HIV hotspots. Youths with TDRMs are likely to have links to others, necessitating intervention in onward transmission.

[1]  H. Xing,et al.  Transmitted HIV drug resistance among individuals with newly diagnosed HIV infection: A multicenter observational study. , 2019, AIDS.

[2]  Ellsworth M. Campbell,et al.  Natural selection favoring more transmissible HIV detected in United States molecular transmission network , 2019, Nature Communications.

[3]  S. Reisner,et al.  HIV pretreatment drug resistance among cisgender MSM and transgender women from Lima, Peru , 2019, Journal of the International AIDS Society.

[4]  L. Ruiz,et al.  The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy , 2019, AIDS.

[5]  M. Hoenigl,et al.  Pretreatment human immunodeficiency virus type 1 (HIV-1) drug resistance in transmission clusters of the Cologne-Bonn region, Germany. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  J. Albert,et al.  Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden , 2018, AIDS.

[7]  P. Harrigan,et al.  Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996-2016. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  D. Chibo,et al.  Analysis of transmitted HIV drug resistance from 2005 to 2015 in Victoria, Australia: a comparison of the old and the new. , 2017, Sexual health.

[9]  V. Veloso,et al.  Transmitted drug resistance in patients with acute/recent HIV infection in Brazil , 2017, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[10]  Ben Murrell,et al.  Social and Genetic Networks of HIV-1 Transmission in New York City , 2017, PLoS pathogens.

[11]  N. Benbow,et al.  HIV-1 Infection and Transmission Networks of Younger People in Chicago, Illinois, 2005-2011 , 2017, Public health reports.

[12]  C. Kang,et al.  The trend of transmitted drug resistance in newly diagnosed antiretroviral-naive HIV/AIDS patients during 1999-2012 in South Korea. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[13]  T. Musa,et al.  Nationwide Trends in Molecular Epidemiology of HIV-1 in China. , 2016, AIDS research and human retroviruses.

[14]  D. Richman,et al.  Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996–2013 , 2016, Journal of acquired immune deficiency syndromes.

[15]  Xiang He,et al.  Geographic origin and evolutionary history of China’s two predominant HIV-1 circulating recombinant forms, CRF07_BC and CRF08_BC , 2016, Scientific Reports.

[16]  Xiang He,et al.  The sexually driven epidemic in youths in China’s southwestern border region was caused by dynamic emerging multiple recombinant HIV-1 strains , 2015, Scientific Reports.

[17]  Alexandros Stamatakis,et al.  RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies , 2014, Bioinform..

[18]  Anne-Mieke Vandamme,et al.  Automated subtyping of HIV-1 genetic sequences for clinical and surveillance , 2013 .

[19]  T. Lam,et al.  The rapidly expanding CRF01_AE epidemic in China is driven by multiple lineages of HIV-1 viruses introduced in the 1990s , 2013, AIDS.

[20]  H. Xing,et al.  Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China , 2012, BMC Infectious Diseases.

[21]  Qinggang Xu,et al.  Phylodynamics of HIV-1 unique recombinant forms in China-Myanmar border: implication for HIV-1 transmission to Myanmar from Dehong, China. , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[22]  Erin K. Rottinghaus,et al.  Optimization of a Low Cost and Broadly Sensitive Genotyping Assay for HIV-1 Drug Resistance Surveillance and Monitoring in Resource-Limited Settings , 2011, PloS one.

[23]  O. Nikolaitchik,et al.  Mechanisms and Factors that Influence High Frequency Retroviral Recombination , 2011, Viruses.

[24]  Hui Li,et al.  Wide Variation in the Multiplicity of HIV-1 Infection among Injection Drug Users , 2010, Journal of Virology.

[25]  Ming Zhang,et al.  jpHMM: Improving the reliability of recombination prediction in HIV-1 , 2009, Nucleic Acids Res..

[26]  Robert J. Gifford,et al.  The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance , 2009, Bioinform..

[27]  S. Vermund,et al.  Estimates of HIV prevalence in a highly endemic area of China: Dehong Prefecture, Yunnan Province. , 2008, International journal of epidemiology.

[28]  Mark Myatt,et al.  Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment , 2008, Antiviral therapy.

[29]  K. Crandall,et al.  Recombination favors the evolution of drug resistance in HIV-1 during antiretroviral therapy. , 2007, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[30]  A. Phillips,et al.  Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.

[31]  Tommy F. Liu,et al.  Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  D. Pillay,et al.  The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy , 2006, AIDS.

[33]  J. Coffin,et al.  Evolution of Human Immunodeficiency Virus Under Selection and Weak Recombination , 2005, Genetics.

[34]  J. Kahn,et al.  Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.

[35]  Y. Takebe,et al.  On-going generation of multiple forms of HIV-1 intersubtype recombinants in the Yunnan Province of China , 2002, AIDS.